Evidence map›Paper›PMID 33176437›Full record

Trial reportCirculation. Heart failure2020

Effects of Omecamtiv Mecarbil on Symptoms and Health-Related Quality of Life in Patients With Chronic Heart Failure: Results From the COSMIC-HF Study.

G Michael Felker, Scott D Solomon, John J V McMurray, John G F Cleland, Siddique A Abbasi, Fady I Malik, Hanze Zhang, Gary Globe, John R Teerlink, COSMIC-HF Investigators

Registry-linked trialOpen access · hybridAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Circulation. Heart failure, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01786512 (A Double-blind, Randomized, Placebo-controlled, Multicenter, Dose Escalation Study to Select and Evaluate an Oral Modified Release Formulation of Omecamtiv Mecarbil in Subjects With Heart Failure and Left Ventricular Systolic Dysfunction), which is not on this map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
1.5field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01786512 phase2completednot on this map

A Double-blind, Randomized, Placebo-controlled, Multicenter, Dose Escalation Study to Select and Evaluate an Oral Modified Release Formulation of Omecamtiv Mecarbil in Subjects With Heart Failure and Left Ventricular Systolic Dysfunction

TypeinterventionalSponsorCytokineticsRan2013 to 2015Enrolled544ConditionsModified Release Oral Formulation, Left Ventricular Systolic Dysfunction, Chronic Heart Failure, History of Chronic Heart FailureArmsOmecamtiv Mecarbil Matrix F1 Formulation, Omecamtiv Mecarbil Matrix F2 Formulation, Placebo, Omecamtiv Mecarbil Swellable Core Technology F2
3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. New Therapeutics for Heart Failure: Focusing on cGMP Signaling.International journal of molecular sciences · 2023
    Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 7 institutions in 2 countries.

G Michael FelkerDuke Clinical Research Institute and Duke University School of Medicine, Durham, NC (G.M.F.).
Scott D SolomonDivision of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA (S.D.S.).
John J V McMurrayBritish Heart Foundation Cardiovascular Research Centre, University of Glasgow, United Kingdom (J.J.V.M.).
John G F ClelandRobertson Centre for Biostatistics, Institute of Health and Wellbeing, University of Glasgow, Glasgow Royal Infirmary, United Kingdom (J.G.F.C.).
Siddique A AbbasiAmgen, Inc, Thousand Oaks, CA (S.A.A., H.Z., G.G.).
Fady I MalikCytokinetics, Inc, San Francisco, CA (F.I.M.).
Hanze ZhangAmgen, Inc, Thousand Oaks, CA (S.A.A., H.Z., G.G.).
Gary GlobeAmgen, Inc, Thousand Oaks, CA (S.A.A., H.Z., G.G.).
John R TeerlinkSection of Cardiology, San Francisco Veterans Affairs Medical Center and School of Medicine, University of California San Francisco (J.R.T.).
COSMIC-HF Investigators
Amgen (United States) · USBrigham and Women's Hospital · USBritish Heart Foundation · GBCytokinetics (United States) · USDuke University · USGlasgow Royal Infirmary · GBSan Francisco VA Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundChronic heart failure with reduced ejection fraction impairs health-related quality of life (HRQL). Omecamtiv mecarbil (OM)-a novel activator of cardiac myosin-improves left ventricular systolic function and remodeling and reduces natriuretic peptides. We sought to evaluate the effect of OM on symptoms and HRQL in patients with chronic heart failure with reduced ejection fraction and elevated natriuretic peptides enrolled in the COSMIC-HF trial (Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure).

methodsPatients (n=448) were randomized 1:1:1 to placebo, 25 mg of OM BID, or to pharmacokinetically guided dose titration (OM-PK) for 20 weeks. The Kansas City Cardiomyopathy Questionnaire was administered to assess HRQL at baseline, 16 weeks, and 20 weeks. The primary scores of interest were the Total Symptom Score, Physical Limitation Scale, and Clinical Summary Score.

resultsMean change in score from baseline to 20 weeks for the Total Symptom Score was 5.0 (95% CI, 1.8-8.1) for placebo, 6.6 (95% CI, 3.4-9.8) for OM 25 mg (

conclusionsHRQL as measured by the Total Symptom Score improved in patients with heart failure with reduced ejection fraction assigned to the OM-PK group relative to placebo. Ongoing trials are prospectively testing whether OM improves symptoms and HRQL in heart failure with reduced ejection fraction. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT01786512.

Indexed as

Quality of LifeAgedBiomarkersChronic DiseaseFemaleHeart FailureHumansMaleMiddle AgedPatient Reported Outcome MeasuresSeverity of Illness IndexStroke VolumeSurveys and QuestionnairesUreaVentricular Dysfunction, LeftBiomarkersomecamtiv mecarbilUreaheart failurelongitudinal studiesquality of lifestroke volumesystole

Identifiers

PMID33176437
PMCPMC7742205
OpenAlexW3103614330

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.